Krupa Patel1, Susan L Zickmund2,3, Harleigh Jones4, Andrea Reid5, Linda Calgaro4, Arielle Otero4, Tami Coppler4, Shari S Rogal4,6,7,8. 1. Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. krupa.patelx@gmail.com. 2. Informatics, Decision-Enhancement and Analytic Sciences Center (IDEAS 2.0), VA Salt Lake City Health Care System, Salt Lake City, UT, USA. 3. Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. 4. VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. 5. Gastroenterology, Hepatology, and Nutrition Section, Washington DC VA Medical Center, Washington, DC, USA. 6. Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, PA, USA. 7. Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. 8. Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
BACKGROUND: Despite the availability of direct acting antiviral medications (DAAs), there are ongoing concerns about adherence to hepatitis C virus (HCV) treatment. We sought to understand the barriers to and facilitators of DAA adherence in the Veteran population. METHODS: Patients completed semi-structured interviews focused on barriers to and facilitators of HCV treatment adherence both pre- and post-DAA treatment. Adherence was assessed via provider pill count and self-report. Thematic analyses were conducted in the qualitative software program Atlas.ti in order to understand anticipated barriers to and facilitators of treatment adherence and completion. Charts were reviewed for clinical data and sustained virologic response (SVR12). RESULTS: Of 40 patients, 15 had cirrhosis and 10 had prior interferon-based treatment. Pre-treatment interviews revealed anticipated barriers to adherence such as side effects (n = 21) and forgetting pills (n = 11). Most patients (n = 27) reported following provider advice, and others had unique reasons not to (e.g., feeling like a "guinea pig"). Post-treatment interviews uncovered facilitators of treatment including wanting to cure HCV (n = 17), positive results (n = 18), and minimal side effects (n = 15). Three patients (8%) did not complete therapy (whom we further elaborate on) and 6 (15%) missed doses but completed treatment. SVR12 was achieved by all participants who completed therapy (93%). Patients who did not complete therapy or missed doses were all treatment naïve, mostly non-cirrhotic (8 of 9), and often anticipated concerns with forgetting their medications. CONCLUSIONS: This qualitative study uncovered several unanticipated determinants of HCV treatment completion and provides rationale for several targeted interventions such as incorporating structured positive reinforcement.
BACKGROUND: Despite the availability of direct acting antiviral medications (DAAs), there are ongoing concerns about adherence to hepatitis C virus (HCV) treatment. We sought to understand the barriers to and facilitators of DAA adherence in the Veteran population. METHODS:Patients completed semi-structured interviews focused on barriers to and facilitators of HCV treatment adherence both pre- and post-DAA treatment. Adherence was assessed via provider pill count and self-report. Thematic analyses were conducted in the qualitative software program Atlas.ti in order to understand anticipated barriers to and facilitators of treatment adherence and completion. Charts were reviewed for clinical data and sustained virologic response (SVR12). RESULTS: Of 40 patients, 15 had cirrhosis and 10 had prior interferon-based treatment. Pre-treatment interviews revealed anticipated barriers to adherence such as side effects (n = 21) and forgetting pills (n = 11). Most patients (n = 27) reported following provider advice, and others had unique reasons not to (e.g., feeling like a "guinea pig"). Post-treatment interviews uncovered facilitators of treatment including wanting to cure HCV (n = 17), positive results (n = 18), and minimal side effects (n = 15). Three patients (8%) did not complete therapy (whom we further elaborate on) and 6 (15%) missed doses but completed treatment. SVR12 was achieved by all participants who completed therapy (93%). Patients who did not complete therapy or missed doses were all treatment naïve, mostly non-cirrhotic (8 of 9), and often anticipated concerns with forgetting their medications. CONCLUSIONS: This qualitative study uncovered several unanticipated determinants of HCV treatment completion and provides rationale for several targeted interventions such as incorporating structured positive reinforcement.
Authors: Julie A Blasiole; Laura Shinkunas; Douglas R Labrecque; Robert M Arnold; Susan L Zickmund Journal: World J Gastroenterol Date: 2006-08-07 Impact factor: 5.742
Authors: Davina Swan; Jean Long; Olivia Carr; Jean Flanagan; Helena Irish; Shay Keating; Michelle Keaveney; John Lambert; P Aiden McCormick; Susan McKiernan; John Moloney; Nicola Perry; Walter Cullen Journal: AIDS Patient Care STDS Date: 2010-12 Impact factor: 5.078
Authors: Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin Journal: J Subst Abuse Treat Date: 2012-10-02
Authors: Donna M Evon; Hannah P Kim; Angela Edwards; Jessica Carda-Auten; Bryce B Reeve; Carol E Golin; Michael W Fried Journal: Dig Dis Sci Date: 2021-02-02 Impact factor: 3.199
Authors: Christer Frode Aas; Jørn Henrik Vold; Svetlana Skurtveit; Ingvild Odsbu; Fatemeh Chalabianloo; Jan Magnus Økland; Rafael Alexander Modahl Leiva; Peter Vickerman; Kjell Arne Johansson; Lars T Fadnes Journal: BMJ Open Date: 2020-08-26 Impact factor: 2.692